BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, February 15, 2026
Home
»
Newsletters
» BioWorld
BioWorld
April 13, 2010
View Archived Issues
Javelin Ending Myriad Merger; Gets Better Deal from Hospira
Read More
Legal 'Markmanship' at Play in Cubist/Teva Generic Fight
Read More
FDA Holds an 'Opening Day' as PDUFA V Debate Begins
Read More
ChemGenex's Omapro Delayed Pending Companion Diagnostic
Read More
Stock Movers
Read More
Clinic Roundup
Read More
Other News To Note
Read More
Financings Roundup
Read More
Appointments And Advancements
Read More
Mersana Inks $334M Teva Deal for Long-Acting Cancer Drug
Mersana Therapeutics Inc. is expected to announce on Tuesday a $334 million deal with Teva Pharmaceuticals Industries Ltd. for XMT-1107, a preclinical revival of the old antiangiogenic drug fumagillin. (BioWorld Today)
Read More
